AMG National Trust Bank Sells 6,656 Shares of Becton, Dickinson and Company $BDX

AMG National Trust Bank lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 84.3% during the second quarter, Holdings Channel reports. The firm owned 1,236 shares of the medical instruments supplier’s stock after selling 6,656 shares during the period. AMG National Trust Bank’s holdings in Becton, Dickinson and Company were worth $213,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Brighton Jones LLC raised its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. FORA Capital LLC bought a new position in Becton, Dickinson and Company in the 1st quarter worth $3,458,000. Cacti Asset Management LLC raised its holdings in Becton, Dickinson and Company by 0.8% in the 2nd quarter. Cacti Asset Management LLC now owns 180,271 shares of the medical instruments supplier’s stock worth $30,801,000 after acquiring an additional 1,500 shares during the period. Baker Tilly Wealth Management LLC grew its position in Becton, Dickinson and Company by 25.4% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 6,898 shares of the medical instruments supplier’s stock worth $1,188,000 after purchasing an additional 1,399 shares during the last quarter. Finally, Northside Capital Management LLC acquired a new stake in Becton, Dickinson and Company in the 2nd quarter worth $7,939,000. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 1,895 shares of company stock worth $358,995. 0.36% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

BDX has been the topic of several research analyst reports. Royal Bank Of Canada restated a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Morgan Stanley raised their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Argus raised their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Piper Sandler restated a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $178.77 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The firm’s 50-day simple moving average is $188.38 and its 200-day simple moving average is $183.04. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The firm has a market cap of $51.24 billion, a P/E ratio of 32.15, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion for the quarter. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.